Derisk you biotech assets with 3 key coniderations.
Learn from drug development expert Angelique Greco and medtech-biotech founders and investors with tangible examples that show how real de-risking plays out.
🔍 What You’ll Learn
Drug discovery feels like a maze when you're early in your career, especially when you're trying to build a biotech path without wasting years or cash. This episode gives you a clear way to turn solid science into something fundable.
You’ll learn:
• Where to find real support, from incubators to honest VC advice
• Why early commercial input matters and how to fix your market slide
• How smart entry points like animal health or adjacent indications de-risk your program and boost your funding chances
Action: Press play if you want 20 minutes that cut months of guesswork.
🧠About the Guest
This episode brings insights from ShanShan Wang (RoamTech AI), Anushi Rajapaksa (Misti), Maryam Parviz (SDIP Innovations), Mike Lamprecht (Tenmile), and Ben Wright (Mimetic MedTech Foundry) on how founders can derisk and resource their team.
Plus why you do not always need an indication at the start, with lessons from Dr Chris Burns, whose team discovered Momelotinib in Australia before its FDA approval.
đź“Ś Episode Highlights
00:00 Why de-risking matters for early biotech founders
00:20 Two angles: advice and smarter indication choices
01:00 How drug discovery fits a STEM entrepreneur path
01:40 Upskilling vs burning cash and time
02:10 Three pillars: compass, investors, venture studios
Roadmap & Upskilling
03:00 The value of a commercialization roadmap
03:45 Han Wang on first seeing the map
04:30 Anushi Rajapaksa on IP, regulatory and evolving the plan
06:00 Where to find training, Bridge program, NSW program
07:00 Why programs matter for network and support
08:00 Maryam Parviz on global doors opening
09:30 What you cannot Google: real conversations
10:30 How informal mentoring happens
11:00 Using tech transfer offices even if you're external
Investor Advice
12:00 Why VC advice matters before fundraising
13:00 Mike Lamprecht on critical early experiments
14:00 What a realistic market conversation looks like
Bridging Your Gaps
15:00 When to stop upskilling and bring experts
15:40 Ben Wright on scaling support instead of solo learning
16:00 How investors view founders who learn on the job
17:00 How venture studios derisk early biotech and medtech
18:00 Why structure and clinical champions matter
Success Exists
18:45 Momelotinib as a real success story
19:10 When starting with the molecule works
20:00 Dr Chris Burns: from discovery to 2023 approval
Smarter Entry Points
22:00 Why some programs need a side door
22:30 What to check before picking an entry point
23:00 Ivermectin from livestock to humans
24:30 Ketamine and S-ketamine into severe depression
26:00 How new IP opened new paths
26:40 The semaglutide pivot
Final Takeaways
27:00 Do not do it alone
27:15 Get advice early, including from VC
27:30 Philanthropy can be a real path
27:45 Be realistic and optimistic, success exists
","author_name":"Angelique Greco | Biotech & Health-Tech Expert | STEM Thought Leadership Coach"}